metricas
covid
Buscar en
Clínica e Investigación en Arteriosclerosis
Toda la web
Inicio Clínica e Investigación en Arteriosclerosis Efectos vasculares y moleculares de los andrógenos endógenos en un modelo expe...
Información de la revista
Vol. 19. Núm. 6.
Páginas 278-286 (noviembre 2007)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 19. Núm. 6.
Páginas 278-286 (noviembre 2007)
Acceso a texto completo
Efectos vasculares y moleculares de los andrógenos endógenos en un modelo experimental en conejos ateroscleróticos
Vascular and molecular effects of endogenous androgens in an atherosclerotic experimental rabbit model
Visitas
4305
Darío Echeverria,
Autor para correspondencia
funcionvascular@cardioinfantil.org

Correspondencia: Dr. D. Echeverri. Laboratorio de Investigación en Función Vascular. Fundación Cardioinfantil-Instituto de Cardiología. Calle 163 A, número 13B-60. Primer Piso. Bogotá. Colombia. funcionvascular@cardioinfantil.org
, Mónica Díazb, Alexandra Delgadilloa, Félix Montesa, Fernando Lizcanob
a Laboratorio de Investigación en Función Vascular. Fundación Cardioinfantil-Instituto de Cardiología. Bogotá. Colombia
b Centro de Investigaciones Biomédicas. Universidad de La Sabana. Chía. Colombia
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Introducción

Existe controversia acerca de los efectos de los andrógenos sobre la aterosclerosis y sus manifestaciones clínicas. El objetivo de este trabajo fue comparar, en conejos ateroscleróticos castrados y no castrados, las características morfológicas, funcionales y la expresión de genes asociados con el metabolismo reverso del colesterol.

Métodos

Cuarenta conejos machos NZ fueron distribuidos en 4 grupos: 1: no castrados, con dieta normal; 2: castrados, con dieta normal; 3: no castrados, con dieta aterogénica, y 4: castrados, con dieta aterogénica. En cada conejo se realizaron mediciones de colesterol total, testosterona libre, relajación vascular in vitro, análisis histomorfométricos de la aorta torácica, y la expresión de genes IL-1β, LRX-α y ABCA1.

Resultados

La castración redujo los valores de testosterona total (2,1±0,3 frente a 0,8±0,4 ng/ml; p=0,024). En animales con dieta normal (grupos 1 y 2), la castración incrementó la expresión de IL-1β (0,71±0,07 frente a 0,77±0,06; p<0,001), redujo LXR-α (0,77±0,008 frente a 0,41±0,01; p<0,001) y aumentó ABCA1 (0,2±0,008 frente a 0,31±0,08; p<0,001). En animales con dieta aterogénica (grupos 3 y 4), la castración se asoció a mayor área de la placa (0,9±1,3 frente a 2,6±2,3 mm2; p=0,026), índice área placa/área vaso (0,08±0,1 frente a 0,25±0,1; p<0,001), índice area placa/área de la media (0,2±0,2 frente a 0,4±0,3; p=0,003), mayor expresión de IL-1β (0,93±0,05 frente a 1,1±0,02; p<0,001), reducción de LXR-α (1,45±0,01 frente a 1,29±0,01; p<0,001) y reducción de ABCA1 (0,22±0,1 frente a 0,20±0,02; p < 0,001).

Conclusiones

Este estudio demuestra que, en presencia de aterosclerosis inducida por hipercolesterolemia, la testosterona endógena podría tener un efecto atenuante o protector de la aterogénesis.

Palabras clave:
Aterosclerosis
Andrógenos
Colesterol
Interleucinas
Introduction

The effects of androgens on atherosclerosis and its clinical manifestations are controversial. The objective of this study was to compare the morphologic and functional characteristics and gene expression associated with reverse metabolism of cholesterol in castrated and non-castrated atherosclerotic rabbits.

Methods

Forty male NZ rabbits were distributed in four groups: 1: non-castrated with a normal diet; 2: castrated with a normal diet; 3: non-castrated with an atherogenic diet, and 4: castrated with an atherogenic diet. Measurements of total cholesterol, free testosterone, in vitro vascular relaxation, histomorphometric analyses of the thoracic aorta and expression of the IL-1β, LRX-α and ABCA1 genes were carried out in each rabbit.

Results

Castration decreased levels of total testosterone (2.1±0.3 vs. 0.8 ± 0.4 ng/mL; P=.024). In animals with a normal diet (groups 1 and 2), castration increased expression of IL-1β (0.71±0.07 vs. 0.77±0.06; P<.001), decreased that of LXR-α (0.77±0.008 vs. 0.41±0.01; P<.001) and increased that of ABCA1 (0.2±0.008 vs. 0.31±0.08; P<.001). In animals with an atherogenic diet (groups 3 and 4), castration was associated with a larger plaque area (0.9±1.3 vs. 2.6 ± 2.3 mm2; P=.026), plaque area/vessel area ratio (0.08±0.1 vs. 0.25±0.1; P<.001), plaque area/media area ratio (0.2±0.2 vs. 0.4±0.3; P=.003), greater expression of IL-1 (0.93±0.05 vs. 1.1±0.02; P<.001), reduction of LXR-α (1.45±0.01 vs. 1.29±0.01; P<.001), and reduction of ABCA1 (0.22 ± 0.1 vs. 0.20 ± 0.02; P<.001).

Conclusions

This study shows that in the presence of atherosclerosis induced by hypercholesterolemia, endogenous testosterone could have an attenuating or protective effect on atherogenesis.

Keywords:
Atherosclerosis
Androgens
Cholesterol
Interleukins
El Texto completo está disponible en PDF
Bibliograf¿a
[1]
for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2007 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007; 115:1-102.
[2]
Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women; Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998; 280:605-13.
[3]
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288:321-33.
[4]
Sex hormones and coronary disease: a review of the clinical studies. Steroids. 1990; 55:30-52.
[5]
Endogenous sex hormones and ischemic heart disease in men. The Caerphilly prospective study. Arterioscler Thromb. 1993; 13:517-20.
[6]
Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women. BMJ. 1995; 311:1193-6.
[7]
The epidemiology of DHEAS and cardiovascular disease. Ann N Y Acad Sci. 1995; 774:259-70.
[8]
Endogenous sex hormones and ischemic heart disease in men. The Caerphilly Prospective Study. Arterioscler Thromb. 1993; 13:517-20.
[9]
Relationships of plasminogen activator inhibitor activity and lipoprotein (a) with insulin, testosterone, 17b-estradiol, and testosterone binding globulin in myocardial infarction patients and healthy controls. J Clin Endocrinol Metab. 1995; 80:1794-8.
[10]
Effect of testosterone on atherogenesis in cholesterol-fed rabbits with similar plasma cholesterol levels. Atherosclerosis. 1993; 99:79-86.
[11]
Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation. 1993; 8:261-9.
[12]
Gender-specific differences in the effects of testosterone and estrogen on the development of atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 1997; 17:2192-9.
[13]
Effects of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responsiveness. Arterioscler Thromb Vasc Biol. 1995; 15:562-70.
[14]
Natural androgens inhibit male atherosclerosis. A study in castrated, cholesterol-fed rabbits. Circ Res. 1999; 84:813-9.
[15]
The relationship of natural androgens to coronary heart disease in males: a review. Atherosclerosis. 1996; 125:1-13.
[16]
Triggering of Plaque Disruption and Arterial Thrombosis in an Atherosclerotic Rabbit Model. Circulation. 1995; 91:776-84.
[17]
A comparative evaluation of the effects of multiple vasodilators on human internal mammary artery. Anesthesiology. 1998; 88:1654-9.
[18]
Reduction of atherosclerosis by administration of dehydroepiandrosterone: a study in the hypercholesterolemic New Zealand white rabbit with aortic intimal injury. J Clin Invest. 1988; 82:712-20.
[19]
Beneficial effects of testosterone on the lipoprotein profile in healthy elderly men: a placebo controlled study. Jpn Heart J. 1997; 38:73-82.
[20]
Endogenous sex hormones and ischemic heart disease in men. The Caerphilly Prospective Study. Arterioscler Thromb. 1993; 13:517-20.
[21]
The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb. 1994; 14:701-6.
[22]
Evidence for an association between dehydroepiandrosterone sulfate and non-fatal, premature myocardial infarction in males. Circulation. 1994; 89:89-93.
[23]
Dehydroepiandrosterone and coronary atherosclerosis. Ann N Y Acad Sci. 1995; 774:271-80.
[24]
Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992; 117:1016-37.
[25]
Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol. 2003; 157:25-31.
[26]
Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab. 2002; 87:3632-9.
[27]
The relationship of natural androgens to coronary heart disease in males: a review. Atherosclerosis. 1996; 125:1-13.
[28]
Aromatase expression in health and disease. Recent Prog Horm Res. 1997; 52:185-213.
[29]
Testosterone as a protective factor against atherosclerosis—immunomodulation and influence upon plaque development and stability. J Endocrinol. 2003; 178:373-80.
[30]
Testosterone relaxes coronary arteries by opening the large-conductance, calciumactivated potassium channel. Am J Physiol Heart Circ Physiol. 2001; 281:H1720-7.
[31]
Testosterone-induced vasorelaxation in the rat mesenteric arterial bed is mediated predominantly via potassium channels. Br J Pharmacol. 2002; 135:735-40.
[32]
Testosterone relaxes human internal mammary artery In-Vitro. J Cardiovasc Pharmacol. 2005; 45:580-5.
[33]
Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size. Proc Nat A Sci USA. 2002; 99:6280-5.
[34]
Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol. 2003; 17:985-93.
[35]
LXRs: new therapeutic targets in atherosclerosis?. Current Opinion Pharmacol. 2003; 3:192-7.
[36]
ABCA1 and atherosclerosis. Vasc Med. 2005; 10:109-19.
[37]
Androgens and cardiovascular disease. Endocrine Reviews. 2005; 24:313-40.
[38]
The roles of androgen receptors and androgen- binding proteins in nongenomic androgen actions. Mol Endocrinol. 2002; 16:2181-7.
[39]
Immunohistochemical evidence for differential distribution of 5a reductase isoenzymes in human skin. Br J Dermatol. 1995; 133:371-6.
[40]
Localized expression of aromatase in human vascular tissues. Circ Res. 1999; 84:1285-91.
[41]
Testosterone inhibits expression of inducible nitric oxide synthase in murine macrophages. Life Sci. 2000; 68:417-29.
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.arteri.2020.12.010
No mostrar más